Raymond James Financial Inc Coherus Bio Sciences, Inc. Transaction History
Raymond James Financial Inc
- $280 Billion
- Q2 2025
A detailed history of Raymond James Financial Inc transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 3,102 shares of CHRS stock, worth $5,087. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,102Holding current value
$5,087% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
119Shares Held
58.2MCall Options Held
89.3KPut Options Held
31K-
Black Rock Inc. New York, NY11.8MShares$19.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$17.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$8.36 Million0.22% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$4.98 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA2.68MShares$4.39 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $127M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...